9 results
6-K
EX-99.1
BYSI
BeyondSpring Inc
21 Sep 21
Current report (foreign)
4:17pm
% of Western and about 70% of Asian NSCLC patients. With immunotherapies moved to first line, docetaxel-based therapies are the mainstay therapy here
6-K
EX-99.1
BYSI
BeyondSpring Inc
5 Aug 21
Current report (foreign)
1:32pm
Oncol. 2013 Sep;14(10):981-8. Large patient population with limited treatment optionsEGFR wild type: ~85% western NSCLC and ~70% of Asian NSCLC patients
20-F
4v2q3ys
28 Apr 17
Annual report (foreign)
12:00am
- Prev
- 1
- Next